SHC Stock Analysis: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$15.75
0.01 (0.06%)
▲
5d:
-2.96%
30d:
+0.25%
90d:
+13.47%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SHC shows positive signals but monitor for confirmation. Market pricing in 3.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: SHC shows positive signals but monitor for confirmation. Market pricing in 3.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.95
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$14.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $15.75, which is considered fair relative to its 30-day fair value range of $15.35 to $16.09. The stock's valuation (Forward PE: 14.8) is in line with its historical norms (16.3). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This pessimistic expectation contrasts with the company's recent 175.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SHC is in a strong uptrend. Immediate support is located at $14.79, while resistance sits at $16.58.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.11 (+27.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SHC is in a strong uptrend. Immediate support is located at $14.79, while resistance sits at $16.58.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.11 (+27.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$15.35 -
$16.09
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.8% below Wall St target ($20.11)
Trading Range Analysis
30-Day Trading Range
$15.35 -
$16.09
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$14.79
Resistance Level
$16.58
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.81
Wall Street Target
$20.11
(+27.8%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
175.4%
Profit Margin
9.9%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
14.8 vs 16.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$15.25
(-3%)
2-Year Target
$14.78
(-6%)
3-Year Target
$14.32
(-9%)
3-Yr Target (if PE normalizes)
(PE: 15→16)
$15.77
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.4%)
$30.28
(+92%)
Base:
(SPY PE: 14.8, Growth: 9.4%)
$20.59
(+31%)
Bear:
(PE: 12.6, Growth: 9.4%)
$17.50
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 38.59 | Current EPS (TTM): $0.41
Bull Case
$34.80
(+121%)
Analyst growth 100.0%, PE expands to 42.4
Base Case
$31.64
(+101%)
Market implied 100.0%, PE stable at 38.6
Bear Case
$10.76
(-32%)
Severe decline -20.0%, PE contracts to 32.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.8 to 16.3
Stabilization Target:
$17.33
(+10.1%)
PE Expansion Potential:
+10.1%
Share & Embed Analysis
Last updated: June 23, 2026 11:11 AM ET
Data refreshes hourly during market hours. Next update: 12:11 PM
Data refreshes hourly during market hours. Next update: 12:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gtcr Investment Xi Llc
SELL
10000000 shares
2026-03-06
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 56 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 51 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 62 BUY |
